anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Despite efforts to achieve UNAIDS 95-95-95 targets, marked deficits remain in HIV testing, antiretroviral therapy (ART) adherence, and viral suppression (VS) among a growing number of persons with HIV (PWH). Gaps in HIV treatment success are particularly pronounced in the United States (US) Deep South. These suboptimal HIV health outcomes occur at a time when clinicians have limited time and the US healthcare system remains fragmented, further exacerbating the challenges inherent in the lives of underserved, marginalized groups, such as PWH. In this way, the development and evaluation of interventions using a resource-savvy cadre of community health workers (CHW) holds promise for addressing these challenges. Yet, gaps exist in the CHW literature, and research is needed to bring CHW interventions to scale to ameliorate the large gaps in the US HIV Care Continuum, particularly in Ending the HIV Epidemic (EHE) priority locations.

In response, the study team has developed and tested the Community Health Workers And MHealth to ImProve Viral Suppression (CHAMPS) intervention which leverages mobile health (mHealth) technology to create a multi-component intervention that targets multiple levels (individual, social and sexual networks, and community) to improve ART adherence and VS. The study team will build on the strong preliminary data of extant intervention work in PWH by leveraging the CHAMPS intervention which will be delivered by personnel from four HIV care settings in the Deep South. The CHAMPS+ intervention is delivered via an mHealth platform to support PWH to self-manage their ART regimens and adds to the extant CHAMPS intervention by adding a CHW-delivered supportive risk reduction counseling (sexual behavior and substance use) during periods of non-suppression to prevent HIV transmission. This study also builds upon mChoice (U01PS005229) and WiseApp (R01HS025071) studies to improve ART adherence and VS in the Deep South. This study design has a three-fold purpose of: 1) engaging the target population in the development of culturally relevant recruitment materials and retention strategies for the study, 2) assessing the clinical effectiveness and sustainability of the intervention in Deep South settings, and 3) evaluating regionalized implementation factors guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework. Ultimately, this study will test CHAMPS+ to promote ART adherence and suppressed viral load for PWH in in Alabama, Louisiana (Orleans Parish), and Mississippi, US EHE prioritized jurisdictions. Importantly, the multi-component intervention targets multiple levels to address HIV risk behaviors during periods of non-suppression--an innovative and impactful component likely to be of great public health import.
PURPOSE:A whitening cosmetic having improved whiteness degree and improved stability, containing a p-dimethylaminobenzoic acid alkyl ester, ethanol and a surface active agent as active ingredients. CONSTITUTION:A whitening cosmetic containing (A) a p-dimethylaminobenzoic acid alkyl ester, (B) ethanol, and (C) a surface active agent as essential components. The alkyl group of the component A has preferably 3-10C, it may have a straight-chain or branched chain, and an amount of the component A blended is preferably 0.1-3wt%. An amount of the component B blended is preferably 1-30wt%, and an amount of the component C blended is preferably 0.1-5 times as much as the component A. The component C is required to have >=10 HLB value,, and any of an anionic, a cationic, or an ampholytic surface active agent or their mixtures may be used. In producing the cosmetic, the component A and the component C is dissolved or dispersed in the component B, and dispersed into a water phase component, to give the aimed cosmetic.
The invention discloses external medicinal liquor for curing stubborn dermatitis, which is obtained by immersing a traditional Chinese medicine composition in liquor for 3-6 months. The traditional Chinese medicine composition comprises the following raw medicines: 90-150 parts by weight of Bletilla, 20-60 parts by weight of Atractylis lancea, 10-30 parts by weight of buttercup coptis chinensis franch, 20-50 parts by weight of high-quality realgar, 20-50 parts by weight of pericarpium zanthoxyli, 20-50 parts by weight of phellodendri, 200-300 parts by weight of golden larch bark, 20-50 parts by weight of ephedra, 20-60 parts by weight of chaulmoogra, 20-50 parts by weight of areca-nut, 20-50 parts by weight of Chinese blister beetle, and 20-50 parts by weight of camphor. All the raw materials of the traditional Chinese medicine composition in the external medicinal liquor are traditional Chinese herbs. The herbs have the effects of clearing heat and eliminating dampness or relieving rheumatic pains and invigorating cold or killing insects. The herbs are mutually compatible, act cooperatively, and have obvious curing effect on the stubborn dermatitis resulted from wind heat wet insects. Furthermore, the external medicinal liquor is convenient to use; active components of the medicines are directly applied on affected parts; the effect is more obvious; furthermore, the external medicinal liquor does not have any toxic and side effects.
Exosomes from cancer cells function as carriers to spread or transport specific microRNAs (miRNAs) to distant sites to exert their effects, but the mechanism of exosomal miRNA action in esophageal squamous cell carcinoma (ESCC) has not been fully explained. Therefore, in this study, we were interested in the impact of exosomal miR-196a-5p in ESCC progression. We found that miR-196a-5p was expressed enriched in clinical tissues, ESCC cells, and exosomes. Functionally, depletion of miR-196a-5p impeded ESCC cell growth, migration, and invasion, whereas overexpression of miR-196a-5p produced the opposite results. Moreover, enhancement of exosomal miR-196a-5p in recipient ESCC cells triggered more intense proliferation and migration. Mechanistically, we identified integral membrane protein 2B (ITM2B) as a direct target of miR-196a-5p. Silencing of ITM2B partially counteracted the inhibitory effect of miR-196a-5p inhibitors on the malignant phenotype of ESCC. Furthermore, in vivo, lower miR-196a-5p levels triggered by the introduction of antagomiR-196a-5p resulted in the generation of smaller volume and weight xenograft tumors. Thus, our results demonstrated novel mechanisms of exosomal and intracellular miR-196a-5p-mediated ESCC growth and migration and identify the interaction of miR-196a-5p with ITM2B. These works might provide new targets and basis for the development of clinical treatment options for ESCC.
Arterial cardiovascular events, i.e. the leading cause of death in patients with JAK2  V617F  myeloproliferative neoplasms (MPN), are poorly understood. The inventors demonstrated that Jak2  V617F  mice display a strong increase in arterial contraction with disturbed endothelial nitric oxide pathway and increased endothelial oxidative stress. This augmented arterial contraction was reproduced by circulating microvesicles isolated from patients carrying JAK2  V617F  and by microvesicles derived from JAK2  V617F  erythrocytes. Using proteomics, the inventors identified a high expression of myeloperoxidase in microvesicles derived from JAK2   V617F  erythrocytes that could account for this effect. To assess the role of myeloperoxidase in this effect, the inventors then directly inhibited myeloperoxidase in microvesicles derived from Jak2  V617F  erythrocytes and observed that it completely reversed the increase in endothelial oxidative stress induced by microvesicles derived from Jak2  V617F  .The results prompt the inventors to conclude that JAK2  V617F  MPN induce a potent increase in arterial contraction with increased endothelial oxidative stress, mediated by erythrocytes microvesicles and that myeloperoxidase (MPO) inhibitors would be suitable for preventing cardiovascular diseases in patient suffering from MPN.
Participants will be in this group for a total of up to 12 months. These participants will receive the intervention via a mobile app.
BACKGROUND AND AIMS: Colorectal cancer (CRC) is a global health challenge, particularly in Alabama, where the incidence rates exceed national averages. This study investigated the factors influencing adherence to post-endoscopic mucosal resection (EMR) colonoscopies, focusing on travel distance and socioeconomic status. This study aimed to provide evidence-based insights to improve patient care in CRC management.
METHODS: This retrospective study in a tertiary care referral center analyzed 465 patients who underwent EMR. The data included demographics, clinical details, and travel-related variables. Descriptive statistics, logistic regression, and spatial analysis were used to assess the factors affecting adherence.
RESULTS: Of 465 patients, 36.6 % had adequate follow-up, 21.8 % had inadequate follow-up, and 41.6 % were lost to follow-up. Noteworthy demographic variations were observed, with median ages differing across adherence groups. Traveled distances showcased compelling insights, indicating a median distance of 22.2 miles for adequate follow-up, 15.7 miles for inadequate follow-up, and 31.6 miles for the lost-to-follow-up group (p<0.001). Longer travel distances were associated with better adherence. Longer travel distances from the hospital were associated with significantly lower odds of inadequate follow-up: 10-25 miles OR:0.29, 25-85 miles OR:0.35, and >80 miles OR:0.24 compared to the first quartile (<10 miles). Socioeconomic factors, particularly educational attainment, significantly influenced the follow-up rates.
CONCLUSIONS: This study revealed suboptimal post-EMR follow-up rates and underscored the impact of travel distance and socioeconomic factors. Targeted interventions addressing distance-related barriers can enhance treatment adherence and ensure timely CRC surveillance after EMR. Further research is needed in diverse healthcare settings.
Anatomically, normal cells found in an abnormal site are known as choristoma. When any two of the three-cell lineage of the mullerian duct, that is endosalpinx, endocervix and endometrium, are found at an abnormal location, it is termed mullerian choristoma or mullerianosis. Mullerianosis histologically reveals glands of varying sizes lined by cervical, tubal and endometrial cells. Individual cell lineages like endometriosis of the ovary, endosalpingiosis and endocervicosis of the urinary bladder are common. But mullerianosis is quite rare, and as per literature, only about 20 cases have been reported. We report a mullerianosis involving the liver and lung in a 41-year-old female that mimicked metastatic biliary cystadenocarcinoma. It is the first case reported in literature where there is simultaneous involvement of the liver and lung by mullerianosis. The diagnosis was made with the help of histopathology and immunohistochemistry in the resected specimens.
Data are collected using the REDCap web application (https://redcap.zhaw.ch/). REDCap is designed for the creation and administration of online surveys. Respondents can access the survey directly via a QR code or link and complete the screening questionnaire via smartphone or computer. In a first step, the participating persons are included or excluded based on the criteria mentioned (chapter: Proband:innen). Once eligibility has been confirmed, the HSQ is completed online for the first time in a second step. After that, the test persons will receive a reminder e-mail after 2 weeks to complete the retest online. After the reminder email the test persons have 2 weeks to complete the retest. Those who participate later will be excluded and not included in the data analysis. In addition, the retest asks whether the headaches have changed compared to the test due to the physiotherapeutic treatment. This is asked with a three Likert scale (not changed, slightly changed, strongly changed). The severely changed headaches are not included in the analysis.

Translated with www.DeepL.com/Translator (free version)
The invention relates to multifunctional platinum (IV) and cyanine dye-based polymers for trimodal imaging-guided chemotherapy-phototherapy, and develops an innovative therapeutic nano-platform based on Pt (IV) prodrugs and near-infrared (NIR) photosensitizers. The Pt (IV) prodrug and cyanine dye (HOCyOH, Cy) are copolymerized and combined into the main chain of the PCPP, and the Cy drug loading and the Pt drug loading of the obtained PCPP NPs are respectively 27.61 percent and 9.37 percent. PCPP NPs are capable of undergoing reductive trigger-multimeric prodrug backbone cleavage and bioactive pt (ii) release; cy was activated under 808nm laser irradiation, generating local hyperthermia and Reactive Oxygen Species (ROS) for phototherapy. In addition, the content of Cy and Pt heavy metals in PCPP NPs frameworks is extremely high, and nano-drugs can be directly tracked in vitro and in vivo through near infrared fluorescence (NIRF) imaging, photothermal imaging and Pt-based CT imaging. Under the guidance of three-mode imaging, PCPP NPs are injected into H22 tumor-bearing mice intravenously, and show good tumor accumulation and anti-tumor effects. The multi-prodrug nano platform with the double-drug framework has great potential in biological imaging and combined chemotherapy.
The project will apply positron emission tomography (PET) of acetylcholinesterase to study non-dopaminergic (i.e. cholinergic) brain changes over time in subjects with Parkinson disease. Acetylcholinesterase PET imaging was used to assess cholinergic changes over time in this study. Acetylcholinesterase PET imaging is a diagnostic test as the investigator does not assign specific interventions to the subjects of the study based on the acetylcholinesterase PET. Therefore, this is an observational study as defined as following: studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
In management of deep caries in primary teeth, the partial caries removal approach favored the arrest of dentin carious lesions, reduced cariogenic micro-organisms and the risk of pulp exposure. The carious tissue at the lateral walls of the cavity at the enamel dentin junction (EDJ) was removed by a spoon excavator without carious tissue removal at the pulpal site. After caries removal, restoration using glass ionomer cement (GIC)(GC Fuji IX™GP extra) was completed. Such an approach is called SMART restoration. The serial radiographs of each restoration consisted of three radiographs; immediately after restoration, at the 6-month follow-up and at the 12-month follow-ups. Digital subtraction radiography(DSR) was used to evaluate dentin remineralization following partial caries removal. Image-Pro Plus software was used to evaluate DSR. For evaluating the changes in DSR, areas with increase density show higher radiopacity, whereas areas with decreased density show higher radiolucency. The 6-month and 12-month follow-up radiographs were subtracted from the baseline radiograph.
Participants received three injections of the CYD Dengue vaccine at 0, 6, and 12 months. Participants were followed for 6 months after the last vaccination (up to 18 months).
Postmenopausal women with breast cancer treated with aromatase inhibitors (AI) have a higher incidence of osteoporosis, fractures and other musculoskeletal symptoms, particularly pain and stiffness. B-ABLE is a clinical, prospective cohort study carried out in both Breast Cancer and Bone Metabolism Units of the Hospital del Mar in Barcelona. Currently, 780 postmenopausal Caucasian women with early breast cancer and candidates for adjuvant AI treatment were included and predicted to reach more than 1000 patients. The main objective of the study is to improve the life quality of women treated with AI. Cohort B-ABLE is designed to evaluate musculoskeletal events derived of using AI in breast cancer women. The project objectives are the analysis of the AI deleterious effect on bone microarchitecture and early determination of the risk of fragility fracture with DEXA, lumbar spine Rx, TBS and microindentation. Determination of physiological causes of the AI-related arthralgia by analyzing joint degradation markers, steroid hormone levels remaining in blood and functional magnetic resonance, before and after three months of AI treatment. The study results will help to decide the most appropriate treatment for each patient in order to minimize AI-related side effects and hence avoid discontinuation of adjuvant therapy treatment.
The invention includes biostructures which may be characterized as having substantially all of the organic-solvent-soluble material in the form of a network of irregularly shaped perforated films. The biostructure may further include particles of a substantially-insoluble material, which may be a member of the calcium phosphate family. The biostructure may be osteoconductive. The biostructure may further contain an Active Pharmaceutical Ingredient or other bioactive substance. The API may be a substance which stimulates the production of bone morphogenetic protein, such as Lovastatin or related substances, thereby making the biostructure effectively osteoinductive. One or more of the polymers may have a resorption rate in the human body such as to control the release of the API. Methods of manufacture are also disclosed.
PURPOSE:To measure the colored rossette number of lymphocytes and to enable easy and quick identification and quantitative determination of various lymphocytes by coloring the gelatin particle groups in a specific grain size range and immobilizing an antibody to one sub-population of the lymphocytes. CONSTITUTION:An aq. soln. prepd. by adding gum arabic or the like used as a thickner or gule, a reactive dye such as metaphosphoric acid, direct blue, egc., and a pigment such as rhodan, etc. to gelatin is adjusted to 2.5-6.0pH and is stirred to obtain colored gelatin particle groups having a 0.1-100mu grain size range. Such insolubilized and colored gelatin particles are then centrifugally separated and after washing, the particle groups immobilized with the antibodies by using tannic acid, formalin, etc. are obtd. The particle groups and the lymphocyte suspension to be measured are brought into reaction with each other. T cells, B cells, etc. form rossettes by bonding with the particles and therefore said rossettes are counted and the result thereof is made helpful for diagnosing various diseases.
The invention relates to managing medications at the bedside. Systems and methods for dispensing medications to hospitalized individuals via a first apparatus containing an optional medication, the apparatus configured to be replenished by the optional medication from a central storage location. Some embodiments provide that the first device is associated with a single patient. The first device is preferably fixed in a location close to the single patient, e.g. in a single patient room. By forming multiple dispensing devices, a caregiver administering a necessary medication need not retrieve an optional medication from a central storage location.
Subjects will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, subjects will continue their famotidine treatment for an additional 9 days.
BACKGROUND: The SCHUMANN study evaluated the efficacy and safety of the selective P2 × 3 antagonist eliapixant in patients with endometriosis-associated pelvic pain (EAPP).
METHODS: SCHUMANN was a randomized, placebo- and active comparator-controlled, double-blind to placebo and open-label to comparator, parallel-group, multicenter, dose-finding phase 2b study. The participants were women with surgically diagnosed endometriosis who fulfilled defined EAPP criteria. Participants were randomized 1:1:1:1 to twice daily (BID) 25 mg, 75 mg, or 150 mg oral eliapixant or a placebo for 12 weeks. An exploratory once-daily elagolix 150 mg treatment group was also included. The primary endpoint was the absolute change in mean worst EAPP from baseline to the end of intervention (EOI).
RESULTS: Overall, 215 participants were randomized for treatment (44 to eliapixant 25 mg, 44 to eliapixant 75 mg, 43 to eliapixant 150 mg, 43 to a placebo, and 41 to elagolix 150 mg). For safety reasons, the study was terminated early; both treatment and enrollment stopped immediately, producing less than 50% of the planned number of completers. The study found no significant differences in EAPP reduction from baseline between groups and no significant dose-response model. The elagolix 150 mg group showed better pain reduction than any of the other groups. No new safety signals were observed, relative to the previously known safety profile of eliapixant, which was generally well tolerated. However, one case of moderate and probably drug-induced liver injury in a participant receiving eliapixant 150 mg BID supported the association between eliapixant and a potential increase in liver function values, defined before the start of the phase 2 program.
CONCLUSIONS: This study did not meet its primary objective as no statistically significant or clinically relevant differences in changes of mean worst EAPP from baseline were observed between treatment groups. The single observed case of moderate, probably drug-induced liver injury was the second case in the eliapixant phase 2 program conducted in the following indications: refractory or unexplained chronic cough, diabetic neuropathic pain, overactive bladder, and EAPP. Due to this, the benefit-risk ratio for the study was no longer considered to be positive.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT04614246; registered November 3, 2020.
BACKGROUND: Intracardiac defibrillator/cardioverter (ICD) is a cornerstone device for prevention of sudden cardiac death. Lead failure (LF) is one of the most important long-term complications. In this study, we sought to investigate mid-to-long term clinical, device and lead characteristics of patients who have undergone pacing sensing lead (PSL) implantation for an ICD LF and compare them to the patients who have undergone a new ICD lead implantation.
METHODS: In this retrospective, single centre, case-control study, we have screened all ICD patients presenting with LF. Patients with IS-1/DF-1 ICD leads with intact high-voltage conductor were included in the study group, while other patients were included in the control arm. Study group patients underwent PSL implantation, control group patients underwent ICD lead implantation.
RESULTS: Thirty patients were included in each arm of the study. The mean duration of follow-up after intervention was similar in both groups (47.6 months ± 20.4 vs. 46.1 months ± 25.7, p = .808). The total failure rate was not different between two groups (p = .640). Rate of high-voltage conductor disfunction was also similar between two arms: 1 (3.3%) in PSL arm and 0 in control arm (p = .303).
CONCLUSIONS: Addition of a PSL for IS-1/DF-1 ICD LF with normal high-voltage conductor measurements is a viable treatment option with similar long-term results to addition of a new ICD lead. This approach is potentially less costly, technically less demanding, and, in case of concomitant extraction procedure, associated with less acute complication risk.